SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, which showcased clinically meaningful benefits and objective evidence of disease modification, positioning it as a potential best-in-class therapy. The strong clinical data and a robust cash position are driving community discussions about its significant undervaluation, potential for a short squeeze, and anticipation of further positive updates at its upcoming Investor Day.

Select Water Solutions, Inc. engages in the provision of water management and chemical solutions. It operates through the following business segments: Water Infrastructure, Water Services, and Chemical Technologies. The Water Infrastructure segment develops, builds, and operates permanent and semi-permanent infrastructure solutions to support full life cycle water management and waste treatment solutions. The Water Services segment consists of services businesses, including water transfer, flowback and well testing, fluids hauling, water containment and water network automation, primarily serving E&P companies. The Chemical Technologies segment includes logistics and provides a full suite of chemicals used in hydraulic fracturing, stimulation, cementing, pipelines and well completions. The company was founded on November 21, 2016 and is headquartered in Gainesville, TX.

Select Water Solutions Inc - Ordinary Shares - Class A

Select Energy Services Inc - Ordinary Shares - Class A

A recently priced public offering of Class A common shares at a 10% discount is sparking conversation around Select Water Solutions, as the community debates the near-term impact of dilution against the company's long-term growth plans for water infrastructure. Many investors are closely watching if robust fundamentals and strong projections for its sustainable water management business will quickly absorb the new shares.

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network is seeing heightened community excitement driven by its upcoming $1 million trading competition and significant protocol developments, including its full return to Ethereum Mainnet for perps trading. Adding to the bullish sentiment, the community is actively discussing the recent end of SNX token inflation and the impending launch of token buybacks, signaling a major shift in its tokenomics.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending following new positive preclinical and clinical data for its inflammatory bowel disease drug, obefazimod, presented at a major medical congress, which is intensifying rumors of a potential acquisition by major pharmaceutical companies. The community is actively discussing a looming bidding war, with many believing the stock is significantly undervalued despite company denials and official statements to the contrary.

Berachain

Berachain (BERA) is generating buzz with its unique Proof-of-Liquidity L1 blockchain, fueled by recent news of a substantial crypto treasury initiative and continuous technical advancements such as programmable wallets. The community is sharply divided, with bulls anticipating significant upside from its growing ecosystem, while bears point to recent price volatility and concerns over token supply.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is generating buzz following the full commercial availability of its Eversense 365 CGM, now integrated with the twiist AID system, which the community hails as a significant leap with its unique year-long wear and superior accuracy. This pivotal development, coupled with hopes for broader market adoption and potential short squeeze activity, occurs amidst ongoing frustration from investors regarding management's commercial execution.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is drawing significant attention as market participants assess the implications of newly implemented 15% global tariffs, leading to polarized community sentiment ranging from predictions of a "bloodbath" amid geopolitical unrest to expectations that the market will quickly rebound, with many also anticipating Nvidia's upcoming earnings.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending after its recent earnings report revealed an EPS miss and a cautious outlook for the coming year, attributed to soft big-ticket consumer spending and a challenging housing market. While some investors view the dip as a long-term buying opportunity given the company's strong Pro segment, others are focused on persistent macroeconomic headwinds and the tempered growth forecast.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render Token is trending following significant new funding and its increasing prominence in the booming decentralized AI compute and DePIN sectors. While many in the community view recent price movements as a chance to accumulate for long-term growth, others express strong skepticism about its current valuation and future trajectory.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending due to widespread community discussion around its pivotal role in the escalating AI infrastructure build-out, with hyperscale giants committing massive capital for custom AI accelerators and networking solutions. Many anticipate a strong upcoming earnings report, driven by expectations of doubling AI semiconductor revenue, while some express frustration with recent market volatility and broader tariff-related concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -26.95% and -131.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics Earnings Report: Q1 Overview

OTLK Stock Crashes 67% in a Week: Here's What You Need to Know

Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.

Wall Street Zen Downgrades Oncobiologics (NASDAQ:OTLK) to Sell

Wall Street Zen downgraded Oncobiologics from a "hold" rating to a "sell" rating in a research report on Saturday...

Futures Blast Off On First Day Of 2026 With Europe, Asia At Records

Futures Blast Off On First Day Of 2026 With Europe, Asia At Records Stocks are set to break a four-day losing streak as markets start the new year with a bang across global markets, boosted by the...

<ul class="summary-bullets"><li>The FDA said it cannot approve the application in its present form for the treatment of wet age-related macular degeneration.</li><li>This marked the second rejection for Outlook’s drug for wet AMD treatment in less than six months.</li><li>The CEO said, “We are disappointed and disagree with this decision.</li></ul>Shares of Outlook Therapeutics (<a href="https://stocktwits.com/symbol/OTLK">OTLK</a>) slumped more than 60% on Friday after it failed to secure U.S. Food and Drug Administration approval for its drug Lytenava, which is intended to treat wet age-related macular degeneration (wet AMD), a chronic eye disorder.This marked the second rejection for Outlook’s drug for wet AMD treatment in less than six months. In August, the FDA declined to approve the drug, citing insufficient evidence of effectiveness, and recommended that the company submit additional data to support its application.In the Complete Response Letter (CRL), the FDA noted that the additional mechanistic and natural history data provided in the biologics license application (BLA) resubmission do not alter the previous review conclusion, adding that the FDA cannot approve the application in its present form for the treatment of wet age-related macular degeneration.“We are disappointed and disagree with this decision, but we remain fully committed to taking all necessary steps to receive approval in the United States,” Bob Jahr, Chief Executive Officer of Outlook Therapeutics, said in a statement.Lytenava has been granted marketing authorization by the European Commission in the EU and marketing authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around OTLK trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes.<figure class="image"><img style="aspect-ratio:636/66;" src="https://news.stocktwits-cdn.com/otlk_3_PNG_39a4a7c8e1.webp" alt="Retail sentiment around OTLK trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes." width="636" height="66"></figure>However, the latest blow from the FDA has disappointed retail traders, with one user saying, “Even if they have money, they have proven approval is beyond their abilities.”<figure class="image"><img style="aspect-ratio:651/132;" src="https://news.stocktwits-cdn.com/OTLK_USER_1_PNG_ebd1b97a3d.webp" alt="latest blow from the FDA has disappointed retail traders, with one user saying, “Even if they have money, they have proven approval is beyond their abilities.”" width="651" height="132"></figure> The FDA disapproval prompted users to believe the company would do cost-cutting. With one user saying to expect the next PR to be cost-cutting and layoffs, followed by dilution, and yet another reverse split.<img src="https://news.stocktwits-cdn.com/otlk_4_PNG_f4b526073b.webp" alt="otlk 4.PNG">Shares of Outlook Therapeutics were down nearly 17% in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Outlook Therapeutics Tanks Over 60% On Another FDA Blow – Here’s How Retail Is Reacting 

OTLK Stock - The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.

A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares 

Equity

The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.

Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again

Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.read more...

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Hold" from Analysts

Oncobiologics, Inc. (NASDAQ:OTLK - Get Free Report) has been assigned an average rating of "Hold" from the six analysts that are covering the firm, Marketbeat reports. One equities research analyst...

Oncobiologics (NASDAQ:OTLK) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

Ascendiant Capital Markets upped their target price on shares of Oncobiologics from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Monday...

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Current Price	$0.4131
Prev Close	$0.4346
Open	$0.437
Dividend Yield	0.00%
50-Day Moving Average	$0.9713
Beta	0.71
Avg. Volume	10.69M
PE Ratio	-0.38

52-Week High	$3.39
52-Week Low	$0.3801
Market Capitalization	$34.32M
EPS (Annual)	-$1.79
Price to Book	-0.69
Revenue Per Employee	$83,149.12

OTLK
Outlook Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OTLK News

OTLKOutlook Therapeutics Inc